Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 3/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.35 |
| ▸ | PRCP | P42785 | 2/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.33 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6126830 | 0.85 | HPGDS (0.46) | HPGDSPRCPSSTR3 | |
| SCHEMBL883169 | 0.85 | HPGDS (0.46) | HPGDSPRCPSSTR3 | |
| SCHEMBL10201134 | 0.85 | USP30 (0.37) | USP30HPGDSGPR119PRCPHCRTR1 | |
| SCHEMBL10182462 | 0.85 | USP30 (0.37) | USP30HPGDSGPR119PRCPHCRTR1 | |
| SCHEMBL689825 | 0.84 | PRCP (0.46) | USP30HPGDSPRCPHCRTR1HCRTR2 | |
| SCHEMBL689826 | 0.84 | PRCP (0.46) | USP30HPGDSPRCPHCRTR1HCRTR2 | |
| SCHEMBL1293420 | 0.84 | HPGDS (0.42) | USP30HPGDSGPR119PRCPHCRTR1 | |
| SCHEMBL16907949 | 0.84 | HPGDS (0.42) | USP30HPGDSGPR119PRCPHCRTR1 | |
| SCHEMBL1293419 | 0.84 | HPGDS (0.42) | USP30HPGDSGPR119PRCPHCRTR1 | |
| SCHEMBL17249887 | 0.84 | HPGDS (0.42) | USP30HPGDSGPR119PRCPHCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2912031-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-31 | — | — | EP | disclosed |
| US-9561212-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-02-07 | — | — | US | disclosed |
| US-9546160-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160338999-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-24 | — | — | US | disclosed |
| US-9340520-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150252028-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-09-10 | — | — | US | disclosed |
| WO-2014065791-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-01 | — | — | WO | disclosed |
| US-20140012020-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-01-09 | — | — | US | disclosed |
| US-8552047-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-08 | — | — | US | disclosed |
| US-20130121957-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-05-16 | — | — | US | disclosed |
| US-20130028859-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-31 | — | — | US | disclosed |
| WO-2012154777-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012109080-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130028859-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | USP30 2534/4885HPGDS 582/4885GPR119 1895/4885 |
| US-20140012020-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | USP30 2534/4885HPGDS 582/4885GPR119 1895/4885 |
| US-20160338999-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | USP30 2534/4885HPGDS 582/4885GPR119 1895/4885 |
| US-20130121957-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | USP30 2534/4885HPGDS 582/4885GPR119 1895/4885 |
| US-20150252028-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | USP30 2534/4885HPGDS 582/4885GPR119 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.